@article{article_1224514, title={Innovations in the treatment of anemia in chronic kidney failure}, journal={Journal of Bursa Faculty of Medicine}, volume={1}, pages={41–44}, year={2023}, author={Ayar, Yavuz}, keywords={Chronic kidney disease, anemia, hepcidin, HIF-PH inhibitors.}, abstract={Chronic kidney disease (CKD) is a chronic inflammatory process. Inflammation, uremic toxins, deficiency of erythropoietin production, iron deficiency, shortening of erythrocyte lifespan, gastrointestinal losses, etc. lead to anemia in CKD. The prevalence of anemia increases as the CKD stage increases. Hepcidin is an important molecule for the use of iron in anemia. Hypoxia-induced factors (HIF) maintain the continuity of erythropoiesis. This molecule is inactivated by prolyl hydroxylase (PH). HIF-PH inhibitors have come into use in the treatment of anemia due to CKD. This review describes anemia in CKD and the use of HIF PH inhibitors.}, number={2}, publisher={Sağlık Bilimleri Üniversitesi}, organization={None}